Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
Authors:
- 8 January 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 106 (1) , 21-34
Abstract
In 2002, Hoshijima and Chien drew largely theoretical parallels between the dysregulation of the signaling pathways driving cancer and those driving cardiac hypertrophy (Hoshijima M, Chien KR. J Clin Invest . 2002;109:849–855). On the surface, this statement appeared to stretch the limits of reason, given the fact that cancer cells are known for their proliferative capacity, and adult cardiomyocytes are, except under unusual circumstances, terminally differentiated and incapable of re-entering the cell cycle. However, on closer examination, there are numerous parallels between signaling pathways that drive tumorigenesis and signaling pathways that regulate hypertrophic responses and survival in cardiomyocytes. Indeed, this issue appears to be at the core of the cardiotoxicity (often manifest as a dilated cardiomyopathy) that can result from treatment with agents typically referred to as “targeted therapeutics,” which target specific protein kinases that are dysregulated in cancer. Herein, we examine the cardiotoxicity of targeted therapeutics, focusing on the underlying molecular mechanisms, thereby allowing an understanding of the problem but also allowing the identification of novel, and sometimes surprising, roles played by protein kinases in the heart.Keywords
This publication has 77 references indexed in Scilit:
- Novel Agents on the Horizon for Cancer TherapyCA: A Cancer Journal for Clinicians, 2009
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Flying under the radar: the new wave of BCR–ABL inhibitorsNature Reviews Drug Discovery, 2007
- Applying the discovery of the Philadelphia chromosomeJournal of Clinical Investigation, 2007
- Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionNature Reviews Cancer, 2007
- Angiogenesis: an organizing principle for drug discovery?Nature Reviews Drug Discovery, 2007
- Drivers and passengersNature, 2007
- Tyrosine Kinases as Targets for Cancer TherapyNew England Journal of Medicine, 2005
- Rearrangement at the 5' end of amplified c-myc in human COLO 320 cells is associated with abnormal transcription.Molecular and Cellular Biology, 1986
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971